loading...| Preferred Name |
GSK-3 Inhibitor LY2090314 |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116849 |
| CAS_Registry |
603288-22-8 |
| code |
C116849 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 |
| Contributing_Source |
CTRP GDC FDA |
| DEFINITION |
An inhibitor of glycogen synthase kinase-3 (GSK-3), with potential antineoplastic activity. Upon administration, LY2090314 binds to and inhibits GSK-3 in an ATP-competitive manner. This prevents GSK-3-mediated phosphorylation of beta-catenin, which inhibits the subsequent ubiquitination and proteasomal degradation of beta-catenin. This leads to the activation of the Wnt/beta-catenin pathway and the induction of apoptosis in susceptible tumor cells. GSK-3, a serine/threonine kinase, plays a key role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and apoptosis. The Wnt/beta-catenin signaling pathway plays key roles in both cellular proliferation and differentiation. The increased expression of beta-catenin, a transcriptional activator, correlates with decreased cellular proliferation and improved prognosis in select cancers. |
| Display_Name |
GSK-3 Inhibitor LY2090314 |
| FDA_UNII_Code |
822M3GYM67 |
| FULL_SYN |
LY-2090314 LY2090314 LY 2090314 3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione GSK-3 Inhibitor LY2090314 |
| Has_Target | |
| Is_Value_For_GDC_Property | |
| label |
GSK-3 Inhibitor LY2090314 |
| Maps_To |
GSK-3 Inhibitor LY2090314 |
| NCI_Drug_Dictionary_ID |
686910 |
| PDQ_Closed_Trial_Search_ID |
686910 |
| PDQ_Open_Trial_Search_ID |
686910 |
| Preferred_Name |
GSK-3 Inhibitor LY2090314 |
| prefixIRI |
Thesaurus:C116849 |
| prefLabel |
GSK-3 Inhibitor LY2090314 |
| Semantic_Type |
Pharmacologic Substance |
| UMLS_CUI |
C3713994 |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||